Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

KalVista Pharmaceuticals (KALV) Invested Capital (2017 - 2025)

KalVista Pharmaceuticals' Invested Capital history spans 11 years, with the latest figure at $95.4 million for Q2 2025.

  • On a quarterly basis, Invested Capital fell 53.82% to $95.4 million in Q2 2025 year-over-year; TTM through Apr 2025 was $95.4 million, a 53.82% decrease, with the full-year FY2025 number at $95.4 million, down 53.82% from a year prior.
  • Invested Capital hit $95.4 million in Q2 2025 for KalVista Pharmaceuticals, down from $164.4 million in the prior quarter.
  • Over the last five years, Invested Capital for KALV hit a ceiling of $257.2 million in Q2 2021 and a floor of $58.6 million in Q1 2021.
  • Historically, Invested Capital has averaged $144.8 million across 4 years, with a median of $139.3 million in 2023.
  • Biggest five-year swings in Invested Capital: skyrocketed 207.09% in 2021 and later tumbled 53.82% in 2025.
  • Tracing KALV's Invested Capital over 4 years: stood at $257.2 million in 2021, then plummeted by 55.5% to $114.4 million in 2023, then surged by 43.61% to $164.4 million in 2024, then tumbled by 41.96% to $95.4 million in 2025.
  • Business Quant data shows Invested Capital for KALV at $95.4 million in Q2 2025, $164.4 million in Q4 2024, and $134.0 million in Q4 2024.